This study reports on 632 cycles from 105 women who were using the CREIGHTON MODEL FertilityCare™ System to avoid pregnancy and had either a serious reason to avoid pregnancy or some degree of a lack of confidence. A progesterone level was drawn on the third day after the Peak Day as they were charting, and if the progesterone level was 2.3 ng/mL or greater, then ovulation was determined to have passed. If the level was greater than 3.0 ng/mL, this indicated that an absolute period of infertility had begun. In these cases, no pregnancies were observed. In the 27 cycles in which a specific follow-up relative to pregnancy could not be definitively determined, the progesterone levels in all cases were 2.3 ng/mL or greater with 23 of the 27 cycles being 3.1 ng/mL or greater. It is highly unlikely that any of those became pregnant as well. These cycles were collected over thirteen years (2004-2016). Two case presentations are also a part of this article of two families in which the couples had very serious reasons to avoid pregnancy. In these two couples, each of the women was multi-gravid and had no evidence of subfertility or infertility. They used the family planning progesterone level (the Peak Day +3 progesterone level) for a total of 167 cycles over a number of years successfully without a subsequent pregnancy.
This article presents a thirteen-year effort to evaluate the serum progesterone level on the third day after the Peak Day as observed by women charting the CREIGHTON MODEL FertilityCare™ System. It is known that the Peak Day is associated with ovulation, and if the progesterone reaches a certain level, then an absolute period of infertility should follow. In fact, this is what this study reflects.
A special course on Marriage, the Family and Human Sexuality was established at Kenrick-Glennon Seminary in St. Louis so as to assist the seminarians in their better understanding of the Church's teaching relative to natural methods of family planning and women's health care. This article compares the response at the beginning of this three-credit semester course to the same seven-item questionnaire given at the conclusion of the course. The preand postcourse scores were calculated for each of the questions. The scores obtained after the course were all significantly higher than they were before the course with p values ranging from 0.01 to <0.0001. Four of the items showed marked improvement including an understanding of the church's teaching related to natural methods, current methods of natural family planning, the impact of a natural method on a couple's marriage, and also the impact of a natural method on family life. Statistically significant improvement was also seen in their understanding of the topic of natural family planning and the Creighton Model System and its relevance toward the seminarian's vocation, the use of the methods to either achieve or avoid pregnancy, and how contraception and abortion are linked. In these last three items, the level of statistical significance was quite high, although not as high as the other four items. There were 104 seminarians over an eight-year period of time, who provided answers to these questions, both before and after the course. This course was modeled after a course that was initiated at the Pope Paul VI Institute for the Study of Human Reproduction, which was for priests, seminarians, and Catholic leaders, titled Love & Life Unlimited. NONTECHNICAL This is an evaluation of a ten-point, seven-question questionnaire that was utilized at the beginning of a course at Kenrick Seminary in Marriage, Sexuality, Creighton Model and NaProTECHNOLOGY. The same questionnaire was given to the students at the beginning of the course and then two to three months later at the conclusion of the three-credit course. The results show that there is a significant improvement in the seminarians' knowledge and general attitude about natural methods of family planning and suggests that such courses would be beneficial to establish in seminaries throughout the country.
Progesterone support in pregnancy has been in use for over 60 years, having received its start in the 1940s. Its initial use was in patients who had habitual spontaneous abortion caused by luteal phase deficiency. More recently, the administration of progesterone later in pregnancy has been considered to be justified because of an observed decrease in circulating progesterone with the onset of labor, an association of premature labor with decreased progesterone concentrations, and the observation that progesterone has a tocolytic effect. A considerable boost to the use of progestational agents to reduce preterm delivery was received with the publication of two papers which showed a significant reduction in preterm delivery rates with the prophylactic administration of either progesterone or 17-a hydroxyprogesterone caproate. Recently it has been shown, however, that its use is not universal. This may be related to the significant late sequelae that were documented following the in utero exposure of the fetus to the potent steroid diethylstilbestrol (DES) and that this bad experience cast “a long shadow,” In spite of this, the use of progesterone, at least in early pregnancy, is widespread in the various artificial reproductive programs and is growing in its use as an agent to reduce prematurity. Over the years, there has been an extraordinary amount of confusion related to the use of progesterone support in pregnancy. The Food & Drug Administration (FDA) created some of this confusion. In various labeling of progesterone products by the FDA, one of the contraindications to the use of oral progesterone is listed as “known or suspected pregnancy.” And, yet, no such contraindication is identified for the use of progesterone gel. In fact, progesterone gel is indicated for progesterone supplementation or replacement as a part of an assisted reproductive technology (ART) treatment program for infertile women with a progesterone deficiency. To make this even more confusing, oral progesterone, while it was contraindicated in “known or suspected pregnancy,” its official labeling stated that it “should be used during pregnancy only if indicated (see contraindications).” Also, up until very recently, there was a dire “warning” contained in the labeling for USP progesterone injection in sesame seed oil regarding an increased possibility of birth defects. An analysis of the fetal safety of isomolecular progesterone (Pregn-4-ene-3,20-dione) administration during the course of 1,310 pregnancies over a 35-year period of time (1979-2014) was undertaken to address this confusion.
The paper presents the main concepts of NaProTECHNOLOGY. Such problems as family planning effectiveness, targeted hormonal assessment of the menstrual cycle, ovarian hormone and target organ dysfunction, disorders of human ovulation, cooperative progesterone replacement therapy, premenstrual syndrome, postpartum depression, unusual bleeding, infertility and antiadhesion therapy are discussed.
The paper presents the main concepts of NaProTECHNOLOGY. Such problems as family planning effectiveness, targeted hormonal assessment of the menstrual cycle, ovarian hormone and target organ dysfucntion, disorders of human ovulation, cooperative progesterone replacement therapy, premustrual syndrome, postpartum depression, unusual bleeding, infertility and antiadhesion therapy are discussed.
Dr. Thomas W. Hilgers draws on decades of medical experience to provide educational and revolutionary insights into the world of women's health. The NaPro Technology Revolution provides real solutions to real problems such as infertility, repetitive miscarriage, menstrual cramps, postpartum depression, PMS, prematurity prevention, ovarian cysts, hormonal abnormalities, irregular/abnormal bleeding, chronic discharges, polycystic ovarian disease, and family planning. Hilgers sheds light on abnormal ovarian function, an issue that millions of women unknowingly suffer from. His methods have proven to assist infertile couples nearly three times more successfully than those who use In Vitro Fertilization, without the dangers of early abortions, frozen embryos, or high rates of multiple pregnancy. The NaProTechnology Prematurity Prevention Program cuts the rate from the national 12.7% to 7%. The NaPro Technology Revolution discusses what every woman has a right to know about her body, her health, and her future!
Adhesion Prevention · Surgical Technique and Adhesions
A somewhat pessimistic view on the prevention of postsurgical adhesions has developed over the years because rigorous surgical approaches may still result in the formation of postsurgical adhesions. In addition, postsurgical adhesion formation is associated with a significant degree of long-term morbidity. In this article, a surgical technique is presented which allows patients with the most extensive form of pelvic adhesions to undergo reconstructive pelvic surgery with a near–adhesion-free postoperative outcome. This study was undertaken to assess the effectiveness of a comprehensive, well-defined set of surgical techniques, with well-defined additions and subtractions in surgical technique over a period of 23 years and three distinct phases of implementation. This work was a systematic comparison of three case-series evaluated sequentially over time. The three surgical protocols were each completely standardized. This was a systematic comparison of three distinct case series of patients who had extensive pelvic adhesions. Three distinct and standardized surgical protocols were prospectively introduced and adhesion scores before and after surgical treatment were assessed and statistically compared for each of the three case series. Ninety-five (95) patients with extensive pelvic adhesive disease due to endometriosis or pelvic inflammatory disease participated in this assessment. They were chosen because of the extensive nature of their pelvic and adnexal adhesions. There were 26 patients in phase I (1987–1993), 44 patients in phase II (1994–2005), and 25 patients in phase III (2006–2009). Using the American Fertility Society scoring system for adnexal adhesions, the total adhesion score decreased from 33.8 to 18.1 in phase I, from 33.3 to 6.0 in phase II, and from 33.2 to 2.5 in phase III. Each decrease was statistically significant within each phase (P < 0.001). Further, a statistically significant decrease in subsequent adhesion scores (P < 0.01) was observed at the time of second-look laparoscopy, when comparing phases I to II, II to III, and I to III, with the lowest scores obtained with the phase III surgical techniques. With the use of a comprehensive, well-defined set of surgical antiadhesion techniques, it is possible to perform adhesion-free or near adhesion-free reconstructive pelvic surgery. (J GYNECOL SURG 26:31)
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
The CREIGHTON MODEL FertilityCare System (CrMS) rests on a decades-long body of research demonstrating that cervical mucus functions as a physiologically regulated biological valve, opening predictably at the periovulatory estrogen rise and closing in the post-Peak phase. Chapter 15 of Hilgers (2004) synthesizes hormonal, ultrasound, cytologic, and biophysical evidence to establish that a woman's external observation of her Peak Day reliably identifies the fertile window, and documents the system's effectiveness data for both achieving and avoiding pregnancy across a five-study meta-analysis of nearly 1,900 couples.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Polyendocrine metabolic ovarian syndrome (PMOS), formerly polycystic ovary syndrome (PCOS), is far more prevalent than its classic presentation suggests, affecting roughly six percent of reproductive-age women and carrying systemic consequences well beyond fertility disruption. This chapter from the foundational NaProTECHNOLOGY textbook maps the hormonal architecture of the condition, its ovulatory defect patterns, its frequent co-occurrence with endometriosis, and the restorative surgical and cycle-tracking approaches developed at the Pope Paul VI Institute.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Male infertility plays a clinically significant role in a large share of couples who struggle to conceive, yet standard laboratory criteria for semen analysis were designed primarily to predict success with assisted reproduction, not natural fertility. NaProTECHNOLOGY approaches male factor as a diagnosable condition with identifiable root causes, applying medical and surgical options aimed at restoring sperm function and combining that work with fertility-awareness charting to maximize the couple's chances of natural conception.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Luteal phase and early pregnancy progesterone supplementation protocols are detailed, including indications derived from Creighton Model hormone profiles and dosing regimens for intramuscular and vaginal routes. Targeted progesterone support addresses a correctable physiological deficit identified through CrMS-guided monitoring, reducing early pregnancy loss in women with documented luteal insufficiency.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Preterm birth remains a leading cause of perinatal mortality, with rates in the United States rising significantly over the latter half of the twentieth century despite decades of awareness. NaProTechnology's integrated prevention approach, developed at the Pope Paul VI Institute, addresses this problem through systematic risk stratification, hormonal support, infection surveillance, and cervical monitoring across the full course of pregnancy.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
This 2004 textbook chapter by Thomas W. Hilgers outlines the structure and content of the formal introductory session used to enroll couples in the Creighton Model FertilityCare System (CrMS). It covers the biological foundation of fertility charting, the role of cervical mucus as a biomarker of the reproductive cycle, and the educational framework designed to train couples in systematic, real-time cycle observation.
The Care Team · Coordinating With Conventional Care
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Nursing within the NaProTECHNOLOGY practice encompasses preoperative preparation, intraoperative assistance, postoperative monitoring, hormone administration protocols, and patient education on cycle-based treatment timing. Nurses fluent in CrMS charting language and NaProTECHNOLOGY biomarker systems function as clinical integrators, ensuring that laboratory and treatment protocols are executed in alignment with the individualized menstrual cycle data driving each patient's care plan.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
NaProTECHNOLOGY utilizes a defined panel of cycle-phase-specific biomarkers — including targeted progesterone, estradiol, LH, FSH, and prolactin drawn at CrMS-standardized cycle days — to characterize the hormonal profile underlying each patient's reproductive dysfunction. This biomarker summary consolidates reference ranges, collection timing rules, and clinical interpretation frameworks that govern diagnosis and treatment decisions across infertility, endometriosis, recurrent pregnancy loss, and cycle irregularity.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Medical protocols in NaProTECHNOLOGY are cycle-phase-targeted regimens — covering ovulation induction, luteal phase hormonal support, hyperprolactinemia management, thyroid optimization, and pre-conceptual supplementation — derived from the biomarker-defined diagnosis rather than empirical stimulation. Consolidating these protocols in a single reference enables practitioners to apply evidence-based, individualized treatment sequences that address root hormonal pathology while supporting natural conception.
Restorative Care and Assisted Reproduction · Cost and Access Comparisons
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
An economic analysis of NaProTECHNOLOGY compares the total treatment costs and cost-per-live-birth outcomes against assisted reproductive technologies, including IVF, drawing on outcome data from the Pope Paul VI Institute to demonstrate that NaPro's higher per-cycle success rates yield a favorable cost-effectiveness ratio despite comparable or lower upfront expenditures. Because NaProTECHNOLOGY identifies and corrects underlying pathology rather than bypassing it, its resource utilization model supports long-term gynecological health benefits that IVF cannot provide, making the economic case inseparable from the clinical one.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
A comprehensive, thematically organized compendium of citations documents the evidentiary foundations for every clinical protocol and outcome claim presented across the preceding 88 chapters, spanning foundational cervical mucus research through contemporary reproductive endocrinology and surgical outcomes literature. Consolidating this reference architecture in a dedicated chapter provides practitioners and researchers a structured pathway to primary literature, reinforcing that NaProTECHNOLOGY is grounded in a reproducible, peer-reviewed evidence base rather than institutional convention.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Hilgers articulates a programmatic vision for the global expansion of NaProTECHNOLOGY through the continued development of FertilityCare Centers International, advanced medical consultant training, and integration of longitudinal hormonal research into evolving clinical protocols. Establishing a roadmap for research priorities, practitioner education infrastructure, and broader medical acceptance positions NaProTECHNOLOGY as a scalable, restorative alternative to the prevailing ART-centered paradigm in reproductive medicine.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Chapter 13 of Hilgers' NaProTECHNOLOGY textbook establishes a clinical behavioral taxonomy unique to the Creighton Model FertilityCare System, distinguishing between achieving-related and avoiding-related use based on whether a couple's actions increase or decrease the probability of conception. The chapter argues that a "taking a chance" mindset is inherently contraceptive in psychology and must be replaced with intentional, education-grounded behavior that reflects a couple's genuine family planning goals.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Chapter 34 of Hilgers (2004) examines how NaProTechnology cycle charting may identify women at elevated risk for three gynecologic cancers: endometrial, breast, and ovarian. The chapter presents clinical case series and a small prospective study suggesting that observable cycle biomarkers, particularly patterns indicating suboptimal luteal-phase function, may precede diagnosis and could inform earlier evaluation, while calling explicitly for further research to validate these findings.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
The structured protocols used to train and certify FertilityCare Practitioners (FCPs) in the uniform delivery of CrMS instruction are detailed, covering the sequence of follow-up sessions, the use of standardized teaching aids, and quality-control mechanisms that ensure inter-instructor consistency. Standardization is essential to the scientific validity of CrMS data, because chart comparability across practitioners and study populations depends on identical observation and recording conventions.
Hilgers TW et al., 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Endometriotic implants are catalogued across their full morphological spectrum—classic powder-burn lesions, red flame lesions, clear vesicles, white fibrotic plaques, and subtle vascular changes—with photographic documentation guiding surgical recognition. Familiarity with atypical implant appearances is essential because underrecognition of non-pigmented lesions leads to incomplete excision and persistent symptomatology.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Early pregnancy loss encompasses biochemical pregnancy, embryonic demise, and missed abortion, each distinguished by specific hormonal profiles and ultrasound criteria within the NaProTECHNOLOGY surveillance model. CrMS-based cycle identification enables recognition of pregnancy at the earliest stages, allowing timely hormonal intervention when progesterone or estradiol deficits are detected.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
The content and sequence of the introductory and follow-up instructional sessions that constitute the formal CrMS education series are outlined, covering observation technique, recording conventions, and the practitioner-client interaction model. Consistent delivery of these core instructions establishes the behavioral competence required for both family planning use and the medical monitoring applications that NaProTECHNOLOGY depends upon.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Surgical NaProTECHNOLOGY is defined as a cooperative surgical discipline that corrects reproductive pathology identified through CrMS monitoring and targeted diagnostic workup, employing microsurgical and laser techniques that maximize tissue preservation and minimize adhesion formation. The philosophical and technical distinctions from conventional gynecologic surgery are established, emphasizing restorative intent and anatomical precision as core principles.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
NaProTECHNOLOGY uses the Peak Day of the Creighton Model chart — the last day of the most fertile-type cervical mucus — as the reference point for dating conception, providing a biologically grounded alternative to last menstrual period dating that remains accurate across irregular cycles. Precise cycle-based dating improves the clinical interpretation of early pregnancy hormone levels, ultrasound findings, and obstetric gestational age assignments, reducing unnecessary interventions triggered by apparent growth discordance.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Hilgers presents a refined classification of follicular and luteal phase deficiencies grounded in the integration of CrMS mucus pattern characteristics, cycle-phase-targeted estradiol and progesterone profiles, ultrasound folliculometry, and endometrial histology, introducing terminology that links specific chart signatures to defined endocrine subtypes and treatment protocols. Follicular deficiencies -- marked by short or poor-quality mucus phases and suboptimal estradiol -- and luteal deficiencies -- marked by a post-Peak phase under nine days, premenstrual spotting, or blunted serial progesterone curves -- are treated with tailored ovulation induction, cooperative progesterone replacement, and correction of contributing systemic disorders including thyroid dysfunction, hyperprolactinemia, and insulin resistance.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Cumulative pregnancy and live birth data from the Pope Paul VI Institute document NaProTECHNOLOGY outcomes across diagnostic categories including unexplained infertility, endometriosis, PCOD, and tubal disease, with multi-year follow-up that captures pregnancies occurring after continued treatment — a metric not captured in per-cycle ART statistics. These outcomes provide the evidence base for positioning NaProTECHNOLOGY as a first-line rather than last-resort reproductive medicine strategy.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Disruptions along the hypothalamic-pituitary-ovarian axis — including luteal phase deficiency, inadequate LH surges, and follicular maturation failure — are among the most common and underdiagnosed contributors to infertility and recurrent pregnancy loss. Targeted hormone supplementation guided by cycle-specific progesterone and estradiol assays, timed to CrMS biomarkers, restores functional ovulatory and luteal competence without suppressing the axis.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
The sonographic ovulation classification is validated against targeted hormone profiles -- estradiol, LH, and serial post-Peak progesterone (P+3 through P+11) -- drawn at CrMS Peak-anchored time points rather than fixed calendar days. Hormone patterns corresponding to each sonographic category (e.g., absent LH surge in anovulation, progesterone rise without follicle rupture in LUF) confirm that ultrasound morphology reliably reflects the underlying endocrine disorder, establishing the biochemical legitimacy of the classification for clinical diagnosis.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Ectopic pregnancy demands prompt diagnosis and intervention to prevent life-threatening hemorrhage, and NaProTECHNOLOGY's CrMS-guided cycle monitoring enables earlier detection compared to symptom-driven presentations. Surgical management favors salpingotomy with tube preservation when feasible, aligned with the NaProTECHNOLOGY commitment to maintaining reproductive anatomy and future fertility potential.
Hilgers TW et al., 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
The FertilityCare Practitioner (FCP) is the trained educator and coach who teaches the Creighton Model FertilityCare System to clients, standardizes charting methodology, and serves as the primary data interface between the patient and the NaProTECHNOLOGY physician. Accurate, consistent chart data from FCPs directly determines the quality of biomarker interpretation, targeted intervention timing, and longitudinal outcome assessment throughout medical and surgical care.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
NaProTECHNOLOGY (Natural Procreative Technology) is defined as a women's health science that monitors and cooperates with the menstrual and fertility cycles to identify, evaluate, and treat gynecologic and reproductive disorders at their root cause. Unlike suppressive approaches such as hormonal contraception or ART, NaProTECHNOLOGY maintains procreative potential and treats underlying pathology while preserving the human ecology of reproduction.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
CO2 laser vaporization technique for peritoneal and superficial ovarian endometriotic implants is described in detail, covering power density settings, spot size, vaporization depth control, and recognition of adequate treatment endpoints. Complete destruction of all visible implants, facilitated by the near-contact survey, is necessary to achieve durable symptom relief and improvement in fertility outcomes.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Premenstrual syndrome in NaProTECHNOLOGY is defined by a recurrent cluster of symptoms -- including irritability, breast tenderness, bloating, depression, and carbohydrate craving -- beginning at least four days before menses, and is associated with late-luteal deficiencies in progesterone, estrogen, and beta-endorphin identified through CrMS-anchored hormone profiling. Treatment with cycle-synchronized bioidentical progesterone, targeted HCG injections to stimulate endogenous corpus luteum function, and low-dose naltrexone to modulate opioid dynamics produces superior symptom resolution compared to SSRI therapy in Hilgers' comparative data, without suppressing ovulation.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Proximal tubal occlusion at the uterotubal junction, whether from salpingitis isthmica nodosa, fibrosis, or prior sterilization, requires cornual resection and microsurgical tubal reimplantation to re-establish luminal continuity. NaProTECHNOLOGY treats this as a reconstructive procedure rather than a reason to defer to IVF, and outcomes data support intrauterine pregnancy rates comparable to assisted reproduction in appropriately selected patients.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
The institutional architecture supporting the CrMS — including the FertilityCare Centers of America network, the American Academy of FertilityCare Professionals (AAFCP), training and certification pathways, and the research programs of the Pope Paul VI Institute — is described. This infrastructure is what distinguishes NaProTECHNOLOGY from informal fertility awareness methods, providing the professional standards, peer accountability, and ongoing research capacity required for clinical credibility.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Serial transvaginal ultrasound monitoring of follicular dynamics -- growth, rupture, corpus luteum formation, and free fluid -- forms the basis of a systematic classification of human ovulation disorders, including anovulation, luteinized unruptured follicle (LUF), follicular arrest, premature luteinization, and PCOS-type patterns. Anchoring sonographic findings to the CrMS Peak day allows precise correlation between ultrasound events and cervical mucus biomarkers, creating a reproducible diagnostic taxonomy that drives targeted medical and surgical treatment within the NaProTECHNOLOGY framework.
Hilgers TW et al., 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Patients who have undergone multiple failed IVF cycles and are counseled to abandon fertility treatment represent a significant NaProTECHNOLOGY cohort in whom undiagnosed correctable pathology — including subtle endometriosis, luteal insufficiency, or immunological factors — is subsequently identified and treated. Published data demonstrate clinically meaningful pregnancy rates in this population following NaProTECHNOLOGY evaluation and treatment, demonstrating that ART failure does not predict failure of restorative approaches.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Adaptations of CrMS instruction for physiologically distinct reproductive states — including breastfeeding, post-hormonal contraceptive use, long or irregular cycles, and premenopause — are described with specific observational guidance for each context. These special protocols extend the clinical reach of the CrMS to all phases of a woman's reproductive life and ensure that charting remains interpretable even when cycle dynamics are atypical.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Structured postoperative management following PEARS procedures addresses wound care, pain control, early ambulation, hormonal support, and surveillance for complications including bleeding, infection, urinary injury, and bowel complications. NaProTECHNOLOGY postoperative protocols integrate CrMS-guided hormonal monitoring to optimize the healing environment and time the resumption of targeted fertility treatment.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Preconceptional optimization using CrMS cycle data establishes hormonal baselines, identifies correctable pathologies, and guides targeted supplementation before conception is attempted. Systematic preconceptional evaluation reduces early pregnancy loss and improves obstetric outcomes by ensuring the endocrine environment supports implantation and early embryonic development.
Fertility and Outcomes · Conception After Excision
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Endometriosis impairs fertility through direct mechanical distortion of pelvic anatomy, peritoneal inflammatory mediators, and hormonal micro-environment alterations that reduce implantation potential, making thorough surgical excision critical to restoring fertility rather than bypassing it. The PEARS classification system, used in NaProTECHNOLOGY surgical practice, enables standardized documentation of endometriotic disease extent and correlates operative findings with postoperative reproductive outcomes.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Unusual uterine bleeding -- including premenstrual spotting, tail-end brown bleeding, mid-cycle intermenstrual bleeding, and heavy menses -- is evaluated in NaProTECHNOLOGY through prospective CrMS charting combined with cycle-phase-targeted estradiol and serial post-Peak progesterone profiles, which typically reveal luteal phase deficiency, follicular estradiol insufficiency, or anovulation as the primary etiology. Treatment is etiology-directed and cycle-synchronized: cooperative progesterone replacement for luteal defects, follicular support or ovulation induction for follicular phase insufficiency, and fertility-sparing surgical correction for structural pathology such as endometriosis, polyps, or fibroids, without routine recourse to contraceptive suppression.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Escalating rates of contraceptive use, abortion, divorce, child abuse, teenage pregnancy, and out-of-wedlock births over the preceding four decades are documented as interconnected indicators of systemic failure in women's and family healthcare. Hilgers argues these trends reflect a prevailing medical culture that suppresses or bypasses reproductive function rather than supporting it, establishing the clinical and moral imperative for a restorative alternative.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Deep infiltrating endometriosis involving the rectosigmoid, appendix, and small bowel is addressed through gynecologist-performed PEARS techniques that include superficial disc excision, appendectomy, and coordinated bowel resection when full-thickness involvement requires it. Recognition of intestinal endometriosis at laparoscopy and command of the relevant surgical steps allow the NaProTECHNOLOGY surgeon to treat the complete disease burden in a single operative setting.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
The Creighton Model's standardized daily vulvar observation system -- recording discharge color, consistency, quantity, and sensation -- allows chronic pathological discharges (persistent yellow or cloudy mucus, continuous post-Peak discharge, premenstrual brown bleeding, or refractory vulvovaginitis) to be distinguished from normal cyclical mucus patterns and tracked longitudinally as a diagnostic tool. NaProTECHNOLOGY uses chronic discharge patterns as biomarkers that prompt organism-specific cultures, targeted hormonal evaluation, ultrasound, and etiology-directed treatment -- including antimicrobials, cooperative hormone replacement, or fertility-sparing surgery -- rather than empirical cycle suppression.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Endometriosis recurrence after surgical excision remains a clinical reality driven by residual ectopic implants, persistent hormonal milieu favoring re-seeding, and incomplete initial resection. NaProTECHNOLOGY addresses recurrence risk through postoperative hormone normalization guided by CrMS biomarkers, with repeat PEARS reserved for symptomatic or fertility-impairing recurrence confirmed by clinical and laparoscopic assessment.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Hilgers distinguishes isomolecular hormones -- molecules structurally identical to endogenous estradiol and progesterone -- from heteromolecular artimones, his term for synthetic analogues such as medroxyprogesterone acetate, norethindrone, and ethinyl estradiol, which differ in receptor binding, metabolic pathways, and systemic effects. NaProTECHNOLOGY restricts hormone therapy to isomolecular compounds administered in cycle-synchronized, physiologic doses because artimones suppress the hypothalamic-pituitary-ovarian axis, mask underlying pathology, and produce non-physiologic metabolite profiles incompatible with a restorative reproductive medicine approach.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
A CrMS-synchronized hormone sampling protocol is detailed in which progesterone, estradiol, and other reproductive hormones are drawn at cycle-phase-specific time points defined by the charted Peak Day rather than by fixed cycle day, producing a targeted hormone profile that accurately reflects luteal and follicular function. This Peak Day-referenced approach substantially improves the diagnostic sensitivity for luteal phase deficiency, follicular dysfunction, and other endocrine abnormalities that fixed-day sampling routinely misclassifies.
Thyroid and Metabolic Function · Thyroid Disorders
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Infertility is not merely a reproductive inconvenience but frequently signals systemic or hormonal pathology — including polycystic ovarian disease, endometriosis, thyroid dysfunction, and immune abnormalities — each carrying independent health risks beyond failure to conceive. Identifying and treating these underlying conditions reduces long-term morbidity and reframes infertility evaluation as a form of preventive medicine rather than a terminal bypass decision.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Chronic pelvic pain and dysmenorrhea in reproductive-age women most commonly reflect undertreated endometriosis, adenomyosis, ovarian dysfunction, or pelvic adhesive disease rather than psychosomatic pathology. NaProTECHNOLOGY evaluates these symptoms through a structured diagnostic pathway integrating CrMS biomarker profiles, hormonal assays, and targeted laparoscopy, directing restorative surgical and medical interventions rather than suppressive hormonal therapy.
Hilgers TW et al., 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Compounding pharmacists prepare individualized hormone formulations — including HCG, progesterone, and thyroid preparations — that are central to NaProTECHNOLOGY treatment protocols, where standardized commercial doses are often inadequate for patient-specific needs. Collaborative prescribing between NaPro practitioners and licensed compounding pharmacists ensures consistent bioidentical formulation quality, dosing precision, and regulatory compliance within fertility and reproductive endocrine management.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Chronic anovulation and progesterone or estradiol deficiency identified through CrMS charting represent periods of suboptimal bone accrual in women of reproductive age, because both estradiol and progesterone contribute to skeletal maintenance -- estradiol through suppression of osteoclast activity and progesterone through osteoblast stimulation. NaProTECHNOLOGY uses longitudinal CrMS records of ovulatory status and hormone profiles as a bone-health risk screen, guiding cycle-synchronized bioidentical hormone replacement to restore normal estrogen-progesterone balance and potentially mitigate progression toward osteoporosis in women with chronic cycle-based endocrine deficiencies.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Distal tubal occlusion — including hydrosalpinx, fimbrial agglutination, and peritubal adhesions — is a correctable cause of tubal-factor infertility amenable to salpingoneostomy, fimbrioplasty, and adhesiolysis under PEARS principles. Restoration of distal tubal patency and normal fimbrial architecture allows natural conception and avoids the bypassing of physiological fertilization that characterizes assisted reproductive technology.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Postpartum depression in susceptible women is linked to abrupt postpartum progesterone withdrawal following the high-progesterone state of pregnancy, particularly in those with prior PMS, luteal phase defects, or recurrent miscarriage, and NaProTECHNOLOGY evaluates this through serum progesterone, thyroid function, and prolactin assessment in the postpartum period. Treatment uses bioidentical progesterone -- preferably intramuscular for reliable absorption -- with serum levels monitored every two weeks for dose titration, and once cycles resume, dosing is resynchronized to the CrMS Peak day; Hilgers reports no increase in congenital anomalies in over 2,000 progesterone-supported pregnancies in the Pope Paul VI Institute series.
Measurement and Statistics · Research Tooling and Reproducibility
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Serum estradiol and progesterone assays vary substantially across laboratories because of differences in antibody specificity, calibration standards, detection platforms, and quality-control practices, meaning that a value within one laboratory's generic reference range may represent a clinically significant deficiency when interpreted against NaPro Peak-day-specific norms. NaProTECHNOLOGY requires consistent use of a single reference laboratory and interpretation relative to cycle-phase-specific NaPro standards rather than broad lab-generated reference intervals, to avoid missing subtle follicular or luteal phase defects that standard reporting would classify as normal.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
CrMS charting features -- Peak day definition, pre-Peak mucus quality and duration, post-Peak phase length, and premenstrual spotting -- are systematically compared against sonographic and endocrine findings to demonstrate that prospective cycle observations reliably identify specific ovulation disorder categories. This clinical validation shows that the CrMS chart functions as a non-invasive biomarker map capable of directing targeted ultrasound and hormonal investigation, and that treatment guided by the classification improves ovulatory and fertility outcomes.
The Care Team · Coordinating With Conventional Care
Hilgers TW et al., 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Family physicians trained in NaProTECHNOLOGY serve as primary coordinators of medical management — prescribing targeted hormone support, monitoring biomarker trends, and triaging surgical referrals — within a collaborative care model. Their longitudinal relationship with patients and ability to integrate reproductive medicine into whole-person primary care is a structural advantage of the NaProTECHNOLOGY delivery system over specialist-only models.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Management of pregnancies complicated by lethal fetal anomalies is addressed within an ethical framework that provides perinatal palliative care, parental support, and medical management without recourse to induced abortion. The chapter outlines clinical protocols for continuing care that respect fetal life while attending to maternal physical and psychological wellbeing through delivery and bereavement.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Laser adhesiolysis protocols address peritubal, periovarian, and cul-de-sac adhesions using CO2 laser energy applied under direct near-contact visualization, with attention to underlying anatomy and vascular proximity. Restoration of normal adnexal mobility and tubo-ovarian relationships is a prerequisite for improved cycle-based fertility after surgical NaProTECHNOLOGY intervention.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
The Creighton Model FertilityCare System (CrMS) is introduced as a standardized, scientifically grounded method for observing and recording cervical mucus biomarkers and bleeding patterns across the menstrual cycle. Its development from earlier natural family planning methods into a fully systematized fertility monitoring tool is traced, establishing the CrMS as the observational substrate for all subsequent NaProTECHNOLOGY medical applications.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Cooperative progesterone and estrogen replacement therapy administers bioidentical hormones in precise synchrony with the woman's CrMS-identified Peak day -- beginning progesterone at P+2 or P+3 and continuing through the luteal phase -- to augment deficient corpus luteum output rather than override the cycle with suppressive dosing. Serial serum progesterone across post-Peak days guides dose titration, and the approach is applied to luteal phase deficiency, recurrent miscarriage, premenstrual syndrome, and postpartum depression while preserving ovulatory function and fertility.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
A photographic atlas documents the intraoperative appearance of endometriosis, adhesions, polycystic ovarian morphology, tubal pathology, and uterine anomalies as encountered during near-contact laparoscopy. Standardized visual reference supports consistent surgical classification, intraoperative decision-making, and communication of findings across the NaProTECHNOLOGY surgical team.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Selective hysterosalpingography combined with transcervical fallopian tube catheterization allows both precise diagnosis and non-surgical correction of proximal tubal occlusion, distinguishing true anatomical obstruction from tubal spasm or mucous plugging. In NaProTECHNOLOGY practice, this minimally invasive approach restores tubal patency without laparotomy, preserving natural conception potential in appropriately selected patients.
Workflow and Documentation · Charting Systems and Records
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
A systematic framework for managing patient cases within the CrMS-NaProTECHNOLOGY system is presented, addressing how FCPs and medical consultants collaborate to identify abnormal chart patterns, initiate medical referral, and coordinate ongoing care. Structured case management is the operational bridge between fertility monitoring and clinical intervention, ensuring that biomarker observations are translated into timely diagnostic and therapeutic action.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Physiological and psychological stress disrupts hypothalamic GnRH pulsatility via CRH-cortisol pathways, producing downstream impairments in LH and FSH secretion that manifest as anovulation, delayed ovulation, follicular phase prolongation, or luteal phase deficiency -- all of which are documented cycle-by-cycle on the CrMS chart. NaProTECHNOLOGY addresses stress-induced HPO axis dysfunction by identifying the specific cycle-level disorder through charting and targeted hormone profiling, then applying cycle-appropriate ovulation induction and cooperative hormone support alongside correction of the underlying physical or psychological stressor.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Three-dimensional ultrasound enables volumetric assessment of uterine architecture, endometrial morphology, and ovarian follicular dynamics with greater anatomical precision than conventional 2D imaging, facilitating detection of septate uteri, submucosal fibroids, and endometriotic lesions that affect implantation. Integration of 3D ultrasound into NaProTECHNOLOGY evaluation protocols enhances the pre-treatment structural workup and informs targeted surgical planning for uterine factor infertility.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Amenorrhea and anovulation represent a spectrum of hypothalamic, pituitary, ovarian, and end-organ etiologies that must be differentiated through systematic hormonal and anatomical evaluation before treatment is initiated. NaProTECHNOLOGY integrates CrMS mucus charting with targeted biochemical testing to identify the level of dysfunction and guide ovulation induction or hormonal restoration appropriate to the specific cause.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Clinical and instructional decision trees guide practitioners through the interpretation of chart findings and the selection of appropriate responses — ranging from continued observation to medical referral — based on pattern recognition and established CrMS criteria. Systematic decision-making protocols reduce practitioner variability, support evidence-based care, and define the threshold at which observed abnormalities warrant further NaProTECHNOLOGY medical evaluation.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Ovarian dysfunction — encompassing luteal insufficiency, abnormal folliculogenesis, and anovulation — is treated in NaProTECHNOLOGY with cycle-timed interventions including HCG trigger, progesterone supplementation, clomiphene, and thyroid optimization, guided by prospective CrMS charting rather than protocol-driven stimulation. This approach normalizes endogenous hormonal patterns rather than overriding them, preserving uterine receptivity and reducing multiple gestation risk.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Bowel endometriosis involving the rectosigmoid, appendix, and small intestine requires specialized resection and repair techniques that fall within the competency of a general surgeon collaborating with the NaProTECHNOLOGY surgical team. Addressing bowel involvement is essential to achieving complete excision of endometriotic disease, which underpins the PEARS philosophy of restoring normal pelvic anatomy and maximizing reproductive potential.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Pelvic adhesions from prior infection, surgery, or endometriosis restrict tubal motility, occlude the fimbriae, and distort ovarian-tubal relationships, constituting a primary mechanical barrier to natural conception. Microsurgical adhesiolysis performed under NaProTECHNOLOGY protocols achieves tubal patency and restores anatomical relationships, enabling natural pregnancy in a substantial proportion of cases that would otherwise be directed to IVF.
Adhesion Prevention · Surgical Technique and Adhesions
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Core microsurgical principles for adhesion prevention—continuous peritoneal irrigation, meticulous hemostasis, minimal thermal spread, avoidance of foreign material, and precise tissue approximation—are detailed as non-negotiable standards in every NaProTECHNOLOGY procedure. Postoperative adhesion formation is the primary cause of surgical failure in pelvic reconstruction, making preventive technique as important as the corrective intervention itself.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Conventional infertility care has shifted toward assisted reproductive technologies that bypass underlying pathology rather than diagnose and treat root causes, leaving a large proportion of couples with unresolved, correctable conditions. NaProTECHNOLOGY addresses this systemic deficiency by emphasizing standardized evaluation, cycle-based hormonal profiling, and targeted medical and surgical treatment before any bypass technology is considered.
Hilgers TW et al., 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Family physicians are optimally positioned to introduce NaProTECHNOLOGY to patients presenting with infertility, irregular cycles, or recurrent pregnancy loss during routine primary care, enabling early evaluation and restorative treatment before referral to subspecialists. Familiarity with CrMS charting interpretation, basic hormone panels timed to identified cycle phases, and the range of treatable NaPro diagnoses allows the family physician to substantially expand reproductive care at the primary care level.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Ovarian wedge resection reduces androgen-producing stromal tissue in women with polycystic ovary syndrome who have failed medical ovulation induction, restoring spontaneous or treatment-responsive ovulatory cycles. Within NaProTECHNOLOGY, the procedure is performed with precise tissue economy and anti-adhesion technique to preserve ovarian reserve while correcting the underlying hormonal dysfunction identified through CrMS biomarker monitoring.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Normal estradiol and progesterone reference ranges in NaProTECHNOLOGY are derived from fertile, ovulatory cycles with confirmed CrMS Peak days and sonographic ovulation, with blood sampling timed to Peak-anchored days (pre-ovulatory P-days for estradiol, P+3 through P+11 for luteal hormones) rather than to calendar cycle days. These day-specific normative values allow detection of subtle deficiencies -- such as a blunted progesterone rise at P+5 or inadequate pre-ovulatory estradiol -- that are clinically actionable for diagnosing follicular and luteal phase disorders but are invisible to standard mid-luteal or phase-independent reference intervals.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
NaProTECHNOLOGY applies the standardized biomarkers of the Creighton Model FertilityCare System to identify the specific pathophysiological causes of infertility in each couple, then directs targeted medical or surgical intervention against those causes. Published pregnancy rates demonstrate outcomes comparable to or exceeding IVF in many diagnostic categories, without the ethical, financial, or obstetric risks associated with assisted reproduction.
Hilgers TW et al., 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Pregnancy achievement rates among couples using the CrMS to target fertile days are analyzed by cycle type, reproductive history, and duration of use, demonstrating the system's capacity to accommodate irregular and abnormal cycles without reducing its fertility-targeting utility. These data are foundational to NaProTECHNOLOGY's application in infertility management, establishing that the CrMS identifies fertile windows even in subfertile populations with disrupted cycle parameters.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Ovarian cysts in NaProTECHNOLOGY are classified as functional (follicular cysts, luteinized unruptured follicle, corpus luteum cysts) or pathological (endometriomas, neoplasms) through serial cycle-timed transvaginal ultrasound correlated with CrMS Peak day observations and post-Peak progesterone and estradiol profiles. Management of functional cysts uses cooperative progesterone replacement and targeted HCG injections to normalize corpus luteum function and reduce cyst recurrence without contraceptive suppression, while pathological or persistent cysts are addressed through fertility-sparing laparoscopic surgery with anti-adhesion technique.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
A quantitative taxonomy for classifying the cervical mucus cycle is established, using standardized descriptors for mucus type, quantity, consistency, and Peak Day timing to produce objectively comparable cycle profiles across patients and study populations. This classification system is indispensable to NaProTECHNOLOGY research and clinical correlation, as it enables the linkage of specific mucus pattern anomalies to underlying endocrine pathology.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
The CrMS charting system is explained in full, including the stamp-based notation for recording mucus characteristics, bleeding, and dry days on the standardized chart, and the conventions for identifying the Peak Day. Accurate chart reading is the foundational clinical skill for NaProTECHNOLOGY practitioners, as the chart provides the biomarker timeline against which hormone profiles and pathology are interpreted.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
The PEARS (Pelvic Endoscopic Adhesion-Related Surgery) procedure for peritoneal and ovarian endometriosis combines near-contact laser vaporization, adhesiolysis, and ovarian cystectomy under strict anti-adhesion protocols to achieve comprehensive disease eradication while preserving ovarian reserve. Outcomes data demonstrate superior fertility and pain resolution compared to incomplete surgical approaches, establishing PEARS as the operative standard within NaProTECHNOLOGY.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Uterine fibroids contribute to abnormal uterine bleeding, dysmenorrhea, recurrent pregnancy loss, and implantation failure, making myomectomy a central NaProTECHNOLOGY surgical intervention for women seeking conception. PEARS myomectomy technique prioritizes uterine preservation, meticulous layered closure of the myometrial defect, and hemostasis strategies that minimize adhesion formation and support subsequent pregnancy.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Extensive pelvic adhesions — often the sequela of prior surgeries, infection, or undertreated endometriosis — distort tubo-ovarian relationships and impair fertility through mechanical obstruction and altered pelvic microenvironment. PEARS adhesiolysis principles emphasize meticulous sharp dissection, copious irrigation, and anti-adhesion adjuncts to restore normal anatomy and optimize postoperative fertility outcomes.
Adhesion Prevention · Surgical Technique and Adhesions
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Postoperative pelvic adhesions are a leading cause of secondary infertility, chronic pain, and bowel obstruction following gynecologic surgery, making adhesion prevention a primary surgical quality metric in NaProTECHNOLOGY. PEARS technique integrates continuous peritoneal irrigation, meticulous tissue handling, avoidance of foreign-body contamination, and selective use of barrier agents to minimize the fibrinous cascade that initiates adhesion formation.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Women with persistent or continuous vaginal discharges — including those from chronic cervicitis, hormonal imbalance, or other gynecologic sources — present a distinct charting challenge, and this chapter provides CrMS-specific protocols for distinguishing pathologic discharge from fertile-quality cervical mucus. Correct identification is clinically critical because misclassification distorts cycle interpretation, effectiveness calculations, and the hormone-assessment timeline.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Both overt and subclinical thyroid dysfunction are recognized in NaProTECHNOLOGY as significant causes of cycle-level reproductive abnormalities -- including oligomenorrhea, anovulation, luteal phase deficiency, heavy bleeding, and recurrent early pregnancy loss -- detectable through CrMS charting before standard screening would prompt thyroid evaluation. The chapter advocates comprehensive thyroid assessment (TSH, free T4, free T3, and thyroid antibodies) with fertility-optimized reference thresholds in women presenting with cycle disorders or infertility, followed by reassessment of CrMS patterns and hormone profiles after thyroid correction to identify and treat any residual follicular or luteal phase defects.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Recurrent spontaneous abortion is examined through a systematic NaProTECHNOLOGY diagnostic framework that includes hormonal, anatomical, immunological, and infectious etiologies identified via CrMS cycle charting and targeted laboratory evaluation. Correcting underlying pathology—particularly luteal phase deficiency and uterine structural abnormalities—achieves live birth rates substantially higher than expectant management alone.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY·
Serial progesterone measurement timed to the luteal phase and early pregnancy using CrMS Peak Day-referenced protocols reveals luteal insufficiency and early placental progesterone inadequacy that are associated with miscarriage risk and preterm labor. Progesterone supplementation guided by these standardized assessments has been associated with reduced pregnancy loss in NaProTECHNOLOGY-managed pregnancies, and the chapter details the specific drawing protocols, reference ranges, and supplementation decision thresholds used in clinical practice.
Over the years of my involvement in obstetrics and gynecology, and reproductive medicine and surgery I have had the opportunity to see, first hand, how the religious liberties of individual physicians, medical students, nurses, patients, etc., have been violated by the contemporary trends in reproductive medicine. Since the advent of oral contraceptives, the practice of obstetrics and gynecology as it relates to procreative medicine has dramatically changed. Contraception, sterilization, abortion and in vitro fertilization are the foundation upon which reproductive medicine decision making is made. These decisions are often made with a "steam roller effect" which is completely devoid of any consent from those who are impacted by the implementation of those decisions. It has been an interesting series of events to watch over these years as the profession has become less and less diagnostically attuned and more and more "band aid" oriented. The birth control pill is used for the treatment of almost every gynecologic malady known, even though it cures none of them. Family physicians, internists, pediatricians and others tend to follow the same approach as their OB-GYN colleagues. With in vitro fertilization, instead of finding out what the underlying cause of one's infertility or reproductive problem might be, there is a "jumping over" of the underlying causes (the diseases) and a pursuit directly to a solution which first of all is very expensive, second, is not very effective and third, is considered to be highly immoral and unethical by many people in our society.
To assess the intratubal pressure (ITP) and patency status of the fallopian tubes before and after transcervical catheterization of the fallopian tubes (TCFT). Prospective procedural assessment. Pope Paul VI Institute for the Study of Human Reproduction. PATIENT(S): Two hundred thirty-four women with either primary or secondary infertility. INTERVENTION(S): Patients underwent selective hysterosalpingography and, in some cases, TCFT with measurement of the ITP before and after the procedure. MAIN OUTCOME MEASURE(S): The ITP before and after TCFT. RESULT(S): The mean (+/-SD) ITP in freely patent tubes was 0.53 +/- 0.06 atm, that in partially obstructed tubes was 1.23 +/- 0.52 atm, and that in completely obstructed tubes was 2.79 +/- 1.40 atm. After TCFT, the mean (+/-SD) ITP in partially obstructed tubes decreased to 0.64 +/- 0.31 atm and that in completely obstructed tubes decreased to 1.86 +/- 1.35 atm. The ITP was normalized in 76% of partially obstructed tubes and in 29.5% of completely obstructed tubes. In all cases of complete obstruction in which surgical correction was attempted, organic pathology was identified. CONCLUSION(S): The procedure described is a safe and easy means of obtaining reliable and significant information on the status of the proximal fallopian tube.
To evaluate the use effectiveness of Creighton Model (CrM) NaProEducation Technology for avoiding pregnancy. CrM is a medical model of natural procreation education that is a fully standardized modification of the Billings ovulation method. This system has been used as a means to avoid pregnancy and has been prospectively evaluated in five use effectiveness studies. A prospective life-table analysis of the five studies (meta-analysis) was undertaken, yielding both net and gross rates. Discontinuation rates were also calculated. These studies were conducted at CrM centers in Omaha, St. Louis, Wichita, Houston, and Milwaukee. A total of 1,876 couples used CrM NET for a total of 17,130.0 couple months of use. The method and use effectiveness rates for avoiding pregnancy were 99.5 and 96.8 at the 12th ordinal month and 99.5 and 96.4 at the 18th ordinal month, respectively. The discontinuation rate was 11.3% at the 12th ordinal month and 12.1% at the 18th ordinal month. CrM is highly effective as a means of avoiding pregnancy in both its method and use effectiveness. The method effectiveness has remained stable over the years of the studies, but the use effectiveness for avoiding pregnancy appears to have improved over the study period.
The optimal timing of sexual intercourse in relation to the day of ovulation in order for pregnancy to result is a topic of broad interest. Of obvious relevance to fecundability, on the one hand, a...
The following is an address presented to a summit meeting on natural family planning sponsored by the Pontifical Councilfor the Family in December, 1992
I am honored and privileged to have this opportunity to be with all of you at this summit meeting on natural family planning. I wish to thank Alfonso Cardinal Lopez Trujillo for his invitation and all ofthe members ofthe Pontifical Council for their generosity and hospitality.
I have been asked to discuss with you what has become known as the Creighton Model Natural Family Planning System. This system obtained its name from my personal association, in its early days of development, with Creighton University School of Medicine in Omaha, Nebraska. This discussion will be, by its very nature, a summary of work that has been done and work that is currently ongoing.
The Creighton Model is referred to as a "model" as opposed to a "method" because it is an integrated education, research and service oriented system which meets the demands of the allied health and medical professions in the field of natural family planning. This system was specifically built to accomplish accountability and competency through a strong professional infra-structure. At the same time, it has been built within the context of a Catholic ethical and moral service delivery framework. It uses a standardized modification of the Billings' Ovulation Method in accomplishing these goals.
I personally became involved in natural family planning with a research project I did as a senior medical student in 1968. As I investigated the salivary albumin concentrations in women during the course of their menstrual cycles, I was looking for a reported decrease in albumin around the time of ovulation. Unfortunately, a project which I had no doubt would solve the problems related to natural family planning (sic), proved to be not a very good idea. . .
"Uterine Isolation" has been discussed, in one form or another, since the early 1940's by such notable American theologians as Fr. John C. Ford, SJ, Fr. Gerald Kelly, SJ; Fr. Francis J. Connell, C.SS.R.; Fr. L. Bender; Fr. John R. Connery; SJ, Fr. Edwin F. Healy, SJ; and Fr. Thomas J. O'Donnell, SJ.l The term "uterine isolation" originated with Fr. O'Donnell. O'Donnell, who is personally convinced of the validity of the arguments for the solid probability of the "uterine isolation" view, was also responsible for having this deleted from the "Ethical and Religious Directives for Catholic Health Facilities" which were published and approved by the bishops in 1971." 'Isolation of the uterus' or 'uterine isolation' " he says, "had taken root in the medical-moral community and, either through misunderstanding or deception, was being used as a presumably morally acceptable semantic for various forms of clearly contraceptive sterilization."l O'Donnell states that the following three points need to be understood by Catholic hospital administration and staff with regard to the term "uterine isolation procedure":
1. Hysterectomy in the presence of a uterus which has been so damaged or weakened by multiple cesarean sections that it is judged to be incapable (because of the damage within the uterus itself) of safely supporting another pregnancy is, with solid probability, not a contraceptive sterilization and is permitted . . . 2. In this case, and only in this case, the isolation of such a uterus at its tubal adnexa, instead of its extirpation, if clinically indicated, is, with solid probability, not a contraceptive sterilization and thus may be permitted and practiced; unless, of course, this is disapproVed by the bishop of the diocese who might well foresee greater harm in the danger of misunderstanding and morally unwarranted extension of the procedure as a semantic to conceal directly contraceptive sterilizations. 3. If, after further study and investigation, there would be a sufficient consensus of theological opinion or a decision by the Congregation for the Doctrine of the Faith that either of the procedures described above (either the hysterectomy in this case or the isolation procedure) is indeed a direct sterilization (such as to discount the solid probability that it is not), then neither of the procedures could be done within the context of Catholic teaching. The sale moral defense of either procedure is the solid probability of the moral opinion that it is not a directly contraceptive sterilization (emphasis applied). I wish to emphasize the need for further study and investigation of this issue because the experience with "uterine isolation" is compelling and proves that the practice is nothing but direct contraceptive sterilization. It is also a practice with inappropriate medical justification . . . a practice which, in the 1990's, cannot be justified on medical moral grounds. One of the most important questions that needs to be asked with regard to "uterine isolation" is "What are we isolating the uterus from?" It is clear that the uterus is not being isolated from either the sperm or the ovum since they present no potential of risk. It is equally clear that the isolation of the uterus, so proposed, is not isolating the uterus from any known disease condition. the only possible thing that this procedure could be isolating the uterus from is a pregnancy . Thus, it seems equally clear that the primary intent of such a "uterine isolation" is contraceptive sterilization. Furthermore, the actual application of "uterine isolation" policies in Catholic hospitals suggests that it is direct contraceptive sterilization.
Hilgers TW et al., 1992·The Journal of reproductive medicine
Fifty consecutive clients achieved pregnancy using a standardization modification of the Billings ovulation method (the Creighton Model Natural Family Planning System). Of 50 clients followed, 38 (76%) achieved pregnancy in the first cycle of fertility-focused intercourse, 45 of 50 (90%) achieved pregnancy by the third cycle and 49 of 50 achieved pregnancy by the sixth cycle (98%).
Fifty consecutive clients achieved pregnancy using a standardization modification of the Billings ovulation method (the Creighton Model Natural Family Planning System). Of 50 clients followed, 38 (76%) achieved pregnancy in the first cycle of fertility-focused intercourse, 45 of 50 (90%) achieved pregnancy by the third cycle and 49 of 50 achieved pregnancy by the sixth cycle (98%).
A simple technique of placing two Kocher clamps on the anterior rectus fascia for the elevation of the anterior abdominal wall during the insertion of the veress needle and the laparoscopic trocar is described in 243 consecutive patients. There were no failed insufflations during this study and no cases of preperitoneal emphysema. The technique is simple to use and adds safety to a basically blind procedure.
The empty follicle syndrome was assessed using transvaginal ultrasonography in a group of 152 consecutive women with unmedicated menstrual cycles being studied because of primary or secondary infertility or repetitive miscarriage. The overall frequency of the empty follicle syndrome was found to be 43.4%. The frequency increased with age but was independent of gravidity. The empty follicle syndrome may be a significant etiologic factor in infertility or other reproductive abnormalities, and transvaginal ultrasound represents a good, non-invasive means of evaluating it.
We report an interesting case of above-normal serum estradiol concentration of unknown origin. A 30-year-old white woman was seen for infertility problems. Hormonal evaluation revealed the following results. Postovulatory progesterone concentrations and profile (a plot of hormone concentration vs time of cycle) were within the normal range for our laboratory (Table 1). However, the post-ovulatory estradiol concentrations were extremely high, although the curve appeared normal in profile (Table 1).
The sonographic definition of the empty follicle syndrome is presented in a group of 89 consecutive, unmedicated menstrual cycles in women with primary or secondary infertility. The incidence of the empty follicle syndrome was found to be 50%. The incidence increased with age and was independent of gravidity or the type of follicular rupture (or lack of rupture). These data suggest that the empty follicle syndrome may represent a significant etiologic factor in infertility or other reproductive abnormalities.
The records of 139 consecutive patients who underwent major gynecologic abdominal surgery in which 32% dextran 70 was used as an antiadhesion adjuvant were carefully reviewed for the presence or absence of dextran-related complications. Eleven patients (8.0%) were thought to have dextran-related complications, including postoperative ileus (2.9%), pleural effusion (2.2%), allergic reactions (1.4%), wound infection (1.4%) and labial swelling (0.7%). The mean amount of dextran used was 183 mL. The study indicated that dextran can be used in moderate amounts when instilled intraperitoneally and has an acceptably low rate of complications. Since dextran is used often in spite of scanty evidence of its effectiveness as an antiadhesion adjuvant, understanding its safety and potential complications is especially important.
The possibility that beta-endorphin, an endogenous opiate, is involved in the regulation of the menstrual cycle was examined. Daily serum beta-endorphin levels, in conjunction with luteinizing hormone, progesterone, and 17 beta-estradiol were measured during 26 hormonally normal menstrual cycles. Twenty-one cycles showed a preovulatory peak and postovulatory trough of beta-endorphin, 2 cycles had a postovulatory peak, and 3 had a postovulatory peak with sustained elevation. The raw data were standardized by conversion to "Z-scores," and the composite values were computed for each of the three classes described above. Significance within these three classes was assessed using a one-way analysis of variance with an F-ratio at 95% confidence limits. The composite plot of the 26 cycles showed a statistically significant preovulatory peak occurring 2 days prior to the luteinizing hormone surge and a postovulatory trough of beta-endorphin 5 days later. These results suggest that beta-endorphins play a significant role in the neurochemical mechanisms of gonadotropin release.
The estimated time of ovulation (ETO) was correlated with the day of defined postovulatory infertility in 66 hormonally normal menstrual cycles from 24 subjects for each of 15 different natural family planning methodologies. Inherent weaknesses were identified in methods based upon calendar calculations or basal body temperature only. These weaknesses could be removed for the basal body temperature-only methods if symptoms, especially the peak mucus symptom, were added to the temperature records. However, the peak mucus symptom alone had the greatest precision of all methods studied. No advantage could be identified in combining the basal body temperature with the peak symptom.
Several periovulatory symptoms sometimes used in natural family planning are correlated with the estimated time of ovulation in 23 subjects and 64 hormonally normal menstrual cycles. The data suggest that intermenstrual pain may not be due to 1 specific cause but rather to several related factors. As a symptom of ovulation, intermenstrual pain was more specific than lower backache, abdominal bloating, and intermenstrual bleeding nonetheless, intermenstrual pain has a broad periovulatory association. The most reproducible and predictable sign of this series appeared to be the postovulatory occurrence of breast tenderness.
Now that principles of NFP have been established specific programs are necessary to disperse information and to teach techniques. The hospital-based NFP program offers the community a needed service and benefits the hospital.
Four points on the basal body temperatures (BBT) curve have been correlated with the estimated time of ovulation (ETO), as determined by indirect hormonal parameters, in 74 menstrual cycles from 24 subjects. Only 10 of 66 hormonally
I read with interest the recent article by Wade and associates, "A randomized prospective study of the use-effectiveness of 2 methods of natural family planning: an interim report" (134: 628, 1979). In reference to the study of the ovulation method, the authors noted that abstinence begins on the 1st day of mucus secretion and continues until the evening of the 4th day beyond the peak or maximal mucus secretion. In the ovulation method, the peak symptom is not the same as maximal mucus secretion as was indicated in the paper. The peak symptom is defined as the last day of the mucus discharge that is clear and/or stretchy and/or lubricative. In the definition of peak symptom, the amount of mucus discharge is not specifically important and may often be misleading. I had the opportunity to do a site visit at this study at the request of the National Institutes of Health while the study was in progress. I analyzed several pregnancies which occurred in users of this ovulation method. Some of the pregnancies occurred as the result of poor teaching of the concept of peak symptom. In the ovulation method, proper understanding and teaching of that concept are essential to the measurement of its effectiveness. Noticeably missing from this interim report was any discussion of the quality control procedures which were utilized to guarantee a high-quality educational service to the people entered into the study. While the authors claim that the methods were taught by professional teachers, these teachers were actually women who had previously used the method and/or had formalized training in teaching the method. Simple use of either of the methods certainly does not qualify an individual to teach natural family planning. For those with formalized teaching, such training should have been outlined since judgment on the effectiveness of the teaching cannot be made; such a judgment is essential to the proper analysis of results. Finally, while the study claims to be a use-effectiveness study, it is rather a modified version of extended use-effectiveness. No objective definition of "user failure" is provided. One cannot ascertain how many pregnancies were related to poor teaching, nor can one tell how many occurred as the result of the couples' last minute exercise of their freedom to use their fertility. The use-effectiveness of the 2 methods under study as a means to achieve a pregnancy have been ignored. In doing so, the investigators have ignored use-effectiveness reality.
It is commonplace for gynecologists to refer to "midcycle" ovulation of women. This concept has often led to the routine diagnosis of ovulatory status on day 14 of what is expected to be a 28-day menstrual cycle. For example, the postcoital test in an infertile patient, or intercourse to achieve pregnancy in a normally fertile patient, is often timed around day 14 under the assumption that ovulation is occurring then. Advocates of natural family planning (NFP) have criticized the concept of "midcycle" ovulation, because their clinical experience suggests that the natural irregularity of menstrual-cycle length militates against ovulation's occurring with any great frequency on day 14.
This report analyzes the relationship of day 14 and the actual midcycle of the menstrual cycle to each other and to indirect hormonal parameters that more directly estimate the time of ovulation.
St. Louis University Natural Family Planning Center. St. Louis. Missouri and Creighton University Natural Family Planning Education and Research Center, Omaha. Nebraska
The observation of the "Peak" mucus symptom in women using the ovulation method of natural family planning has been correlated with the estimated time of ovulation, as evaluated by indirect hormonal parameters. In 65 cycles of the 73 studied in 24 patients, there was hormonal confirmation of ovulation; in eight cycles, anovulation or luteal dysfunction was suspected. In the 65 normal cycles, 64 exhibited a Peak symptom. In those cycles, ovulation was estimated to occur from 3 days before to 3 days after the Peak symptom with a mean of 0.31 days before the Peak symptom. In 95.4% of these cycles, ovulation was estimated to occur from 2 days before to 2 days after the Peak symptom. The variation between cycles of the same patient ranged from 0 to 4 days with a mean of 1.8 days. The beginning of the mucus symptom preceded the estimated time of ovulation by an average of 5.9 days.